Crown WH - Search Results

1

Treatment costs of venlafaxine and selective serotonin-reuptake inhibitors for depression and anxiety.

Wan GJ, Crown WH, Berndt ER, Finkelstein SN, Ling D. Wan GJ, et al. Among authors: crown wh. Manag Care Interface. 2002 Jun;15(6):24-30. Manag Care Interface. 2002. PMID: 12087603

2

Healthcare expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety.

Wan GJ, Crown WH, Berndt ER, Finkelstein SN, Ling D. Wan GJ, et al. Among authors: crown wh. Int J Clin Pract. 2002 Jul-Aug;56(6):434-9. Int J Clin Pract. 2002. PMID: 12166541

3

The impact of treatment-resistant depression on health care utilization and costs.

Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, Russell JM. Crown WH, et al. J Clin Psychiatry. 2002 Nov;63(11):963-71. doi: 10.4088/jcp.v63n1102. J Clin Psychiatry. 2002. PMID: 12444808

4

The cost consequences of treatment-resistant depression.

Russell JM, Hawkins K, Ozminkowski RJ, Orsini L, Crown WH, Kennedy S, Finkelstein S, Berndt E, Rush AJ. Russell JM, et al. Among authors: crown wh. J Clin Psychiatry. 2004 Mar;65(3):341-7. doi: 10.4088/jcp.v65n0309. J Clin Psychiatry. 2004. PMID: 15096073

5

The impact of anaemia and its treatment on employee disability and medical costs.

Berndt E, Crown W, Kallich J, Long S, Song X, Lyman GH. Berndt E, et al. Pharmacoeconomics. 2005;23(2):183-92. doi: 10.2165/00019053-200523020-00009. Pharmacoeconomics. 2005. PMID: 15748092

6

The economic burden of anemia in cancer patients receiving chemotherapy.

Lyman GH, Berndt ER, Kallich JD, Erder MH, Crown WH, Long SR, Lee H, Song X, Finkelstein SN. Lyman GH, et al. Among authors: crown wh. Value Health. 2005 Mar-Apr;8(2):149-56. doi: 10.1111/j.1524-4733.2005.03089.x. Value Health. 2005. PMID: 15804323 Free article.

7

Measuring the costs and benefits of pharmaceutical expenditures.

Crown WH, Ling D, Berndt E. Crown WH, et al. Expert Rev Pharmacoecon Outcomes Res. 2002 Oct;2(5):467-75. doi: 10.1586/14737167.2.5.467. Expert Rev Pharmacoecon Outcomes Res. 2002. PMID: 19807470

8

Benefit plan design and prescription drug utilization among asthmatics: do patient copayments matter?

Crown WH, Berndt ER, Baser O, Finkelstein SN, Witt WP, Maguire J, Haver KE. Crown WH, et al. Front Health Policy Res. 2004;7:95-127. doi: 10.2202/1558-9544.1053. Front Health Policy Res. 2004. PMID: 15612337

9

A framework to evaluate the economic impact of pharmacogenomics.

Stallings SC, Huse D, Finkelstein SN, Crown WH, Witt WP, Maguire J, Hiller AJ, Sinskey AJ, Ginsburg GS. Stallings SC, et al. Among authors: crown wh. Pharmacogenomics. 2006 Sep;7(6):853-62. doi: 10.2217/14622416.7.6.853. Pharmacogenomics. 2006. PMID: 16981846

10

[The costs of treatment with the new antidepressants in clinical practice].

Sacristán JA, Gilaberte I, Hylan TR, Crown WH, Bueno G, Garzón MA, Montejo AL. Sacristán JA, et al. Among authors: crown wh. Aten Primaria. 1999 Jan;23(1):15-6, 18, 20-5. Aten Primaria. 1999. PMID: 10079556 Spanish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

102 results

Search Page

Filters